Study of Intravenous ZMA001 in Healthy Subjects
Study Details
Study Description
Brief Summary
Background:
A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people.
Objective:
To test a drug (ZMA001) in healthy volunteers.
Eligibility:
Healthy adults aged 18 to 60 years.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have a urine test for drug use. They will have a test of their heart function.
Participants will come to the clinic for 1 inpatient visit of up to 48 hours.
ZMA001 is a liquid administered through a tube attached to a needle inserted into a vein in the arm. Participants will receive this drug only once, during their inpatient stay. Some participants will receive the drug; others will receive a placebo. A placebo is a treatment that looks just like the real drug but contains no medicine. Participants will not know which treatment they are getting.
After a screening visit, participants will have 1 inpatient visit and up to 6 outpatient visits over 16 weeks after receiving the treatment. Blood draws and other tests will be repeated. Each outpatient visit is approximately 2 hours long.
This study is the first time ZMA001 will be administered to people.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Study Description:
ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH). The current first-in-human, randomized, double-blind, placebo-controlled, single ascending-dose study will determine the safety, tolerability, and pharmacokinetics of intravenous ZMA001 in healthy subjects.
Objectives:
Primary Objective: Safety and tolerability of ZMA001 in healthy subjects
Secondary Objectives: Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose
Endpoints:
Primary Endpoint: The number of all-cause, treatment-emergent adverse events, grade 1 and above (following CTCAE v5.0 criteria) through day 113
Secondary Endpoints: For each ZMA001 dose level (1.5, 5, 12 and 20 mg/kg), the following will be determined [Timeframe: Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 29, 57, 85 and 113]:
-
Time to peak drug concentration (Tmax)
-
Peak drug concentration (Cmax)
-
Area under the drug concentration-time curve (AUC)
-
Elimination half-life
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Placebo Placebo for ZMA001 is supplied in a single-use 10 mL glass vial. Each vial contains 30 mg/mL of sucrose.Placebo drug is manufactured using the same ingredients as active drug (20 mM histidine-HCl buffer [pH 5.6], 30 mg/mL sucrose, 0.070 w/v% polysorbate 80) excluding ZMA001 antibody and is packed in the same vial. |
Other: Placebo
30mg/ml Sucrose
|
| Experimental: ZMA001 (BC-NKA-20008) ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH). |
Drug: ZMA001 (BC-NKA-20008)
ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
|
Outcome Measures
Primary Outcome Measures
- Safety and tolerability of ZMA001 in healthy subjects [day 113]
The number of all-cause, treatment-emergent adverse events, grade 1 and above (following CTCAE v5.0 criteria) through day 113
Secondary Outcome Measures
- Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose. [Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 29, 57, 85 and 113]
For each ZMA001 dose level (1.5, 5, 12 and 20mg/kg), the following will be determined1. Time to peak drug concentration (Tmax)2. Peak drug concentration (Cmax)3. Area under the drug concentration-time curve(AUC)
Eligibility Criteria
Criteria
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-
Stated willingness to comply with all study procedures and availability for the duration of the study
-
Male* or female, aged 18 to 60 years, inclusive
-
In good general health as evidenced by medical history
-
Females of childbearing potential agree to use an accepted method of contraception (see below) throughout study participation and for 120 days after study drug infusion.
-
Males sexually active with a female partner must agree to use a condom with spermicide for 120 days after study drug infusion or be surgically sterile for at least 90 days before screening. Males must also agree to not donate sperm for 120 days after study drug administration.
-
Agreement to adhere to Lifestyle Considerations throughout study duration
-
Ability of subject to understand and the willingness to sign a written informed consent document.
- Enrollment of healthy male subjects will be limited to no more than 14 out of the total study cohort of 32 in order to ensure an adequate representation of female subjects.
Accepted methods of contraception for females of childbearing potential:
-
Use of an implanted or intrauterine hormonal device for at least 30 consecutive days before study drug infusion
-
Use of oral, patch or injectable contraceptives or a vaginal hormonal device for at least 30 consecutive days before study drug infusion
-
Use of a non-hormonal intrauterine device for at least 30 consecutive days before study drug infusion
-
Two barrier methods such as a diaphragm with spermicide or a condom with spermicide
EXCLUSION CRITERIA:
An individual who meets any of the following criteria prior to informed consent will be excluded from participation in this study:
-
Pregnancy or lactation. Females of childbearing potential must have a negative serum B-human chorionic gonadotropin test no more than 48 hours from study drug infusion.
-
History of severe drug or excipient allergy or hypersensitivity
-
Known allergy to any of the components of the investigational drug or placebo
-
Recent infection or febrile illness within the past 14 days
-
Treatment with another investigational drug within the past 30 days or 5 half-lives, whichever is longer
-
Any vaccination within the past 4 weeks or receipt of a live-attenuated vaccine within the past 6 months
-
Use of tobacco products within the past 3 months
-
Recreational drug use within the past 6 months or positive urine drug screen at Screening Visit
-
History of alcohol abuse within the past 2 years
-
History or current clinically significant medical illness including (but not limited to) hematologic, oncologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, infectious, hepatic, dermatologic, psychiatric, neurologic, autoimmune or allergic disease
-
Use of prescription drugs (except contraceptives) within the past 7 days or 5 half-lives, whichever is longer. Common non-prescription medications such as (but not limited to) acetaminophen, ibuprofen, or anti-histamines are allowed up to 24 hours prior to dosing.
-
Body mass index less than 17 or greater than 32 kg/m^2
-
Clinically significant abnormal results on clinical blood testing completed at the Screening Visit
-
Electrocardiographic evidence of clinically relevant heart disease
-
Use of vitamins, herbal supplements, or similar products within the past 2 weeks
-
Blood donation equal to or above 500 mL within 2 months prior to dosing.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Institutes of Health Clinical Center | Bethesda | Maryland | United States | 20892 |
Sponsors and Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
Investigators
- Principal Investigator: Jason M Elinoff, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 10001522
- 001522-H